Nussberger J, Fleck E, Bahrmann H, Delius W, Schultheiss H P, Brunner H R
University Hospital Lausanne, Switzerland.
Eur Heart J. 1994 Dec;15 Suppl D:113-22. doi: 10.1093/eurheartj/15.suppl_d.113.
Early treatment with ACE inhibitors of even moderate heart failure is clinically beneficial, even though haemodynamic measurements cannot adequately quantitate such improvement. Neurohumoral assessment is, however, supposed to be more accurate. In 55 patients with moderate heart failure (ejection fraction < or = 35%), we investigated the dose-dependent effects of ACE inhibition with quinapril taken orally (2.5, 5 or 10 mg b.i.d.) following a placebo-controlled, parallel design protocol over 12 weeks. Plasma components of the renin angiotensin system, catecholamines and ANF were measured together with haemodynamics both at rest and during exercise. Before ACE inhibitor treatment, median PRA, Ang I and II and catecholamines were normal, while ANF was increased. All these parameters, including ACE activity, rose during exercise. Chronic inhibition of ACE activity was dose-dependent and the maximal fall in Ang II occurred with quinapril 20 mg.day-1. Humoral changes appeared more assessible than haemodynamic alterations even though many of these changes were reasonably correlated. The effects of chronic ACE inhibition on circulating neurohumoral components in patients with moderate heart failure are small and dose-dependent. Since humoral changes are related to haemodynamics they should account for the clinical benefit. Appropriately high doses of ACE inhibitors should be chosen for treatment of heart failure.
即使是对中度心力衰竭患者,早期使用血管紧张素转换酶(ACE)抑制剂在临床上也是有益的,尽管血流动力学测量无法充分量化这种改善。然而,神经体液评估应该更准确。在55例中度心力衰竭患者(射血分数≤35%)中,我们按照安慰剂对照、平行设计方案,口服喹那普利(2.5、5或10mg,每日两次),研究了12周内ACE抑制的剂量依赖性效应。在静息和运动状态下,测量了肾素-血管紧张素系统、儿茶酚胺和心钠素的血浆成分以及血流动力学指标。在ACE抑制剂治疗前,血浆肾素活性(PRA)、血管紧张素I和II以及儿茶酚胺的中位数正常,而心钠素升高。所有这些参数,包括ACE活性,在运动时均升高。ACE活性的慢性抑制呈剂量依赖性,最大的血管紧张素II下降发生在喹那普利剂量为20mg·天-1时。尽管许多这些变化有合理的相关性,但体液变化似乎比血流动力学改变更容易评估。慢性ACE抑制对中度心力衰竭患者循环神经体液成分的影响较小且呈剂量依赖性。由于体液变化与血流动力学相关,它们应该可以解释临床获益。治疗心力衰竭应选择适当高剂量的ACE抑制剂。